基于传统中医药经验使用亚砷酸氯化钠注射液治疗新型冠状病毒肺炎和各种易感病毒引发的严重恶性疾病的推论

Arsenious acid and sodium chloride injection for the novel coronavirus pneumonia and severe malignant diseases caused by Corona viruses and other viruses based on empirical use of traditional Chinese medicine

中药砒霜(即三氧化二砷)辛酸、热,有大毒,归肺、脾、胃、大肠经,有祛痰截疟、杀虫、蚀疮去腐之功效,可用于治疗寒痰哮喘。运用"以毒攻毒"原理,1971年中国用亚砷酸注射液治疗急性早幼粒细胞白血病(APL),疗效显著;1999年国家药品监督管理局药品审评中心(CDE)批准哈尔滨医大药业股份有限公司生产亚砷酸氯化钠注射液(AASCI),2000年9月美国FDA批准生产亚砷酸注射液,2001年欧洲批准生产AASCI。AASCI已在肝、肺、胰、胃、骨、淋巴等器官实体瘤的治疗中发挥重要治疗作用,但在抗病毒方面鲜少应用。结合1760年张宗法著的《三农纪》中关于砒霜可治疗瘟疫的记载、古老的砒霜卡耳法应用历史和20世纪90年代中国治疗猪瘟的结果,证明亚砷酸可高效杀死恶性病毒。因此,笔者基于传统中医药治疗瘟病经验,提出推论:以三氧化二砷为主药的AASCI可能有效治疗新型冠状病毒肺炎和各种冠状病毒、流感病毒等引发的严重恶性疾病,预推治疗剂量为0.16 mg/(kg·d),用药时间1~6周,同时使用基础治疗药物,但该药有剧毒,必须在临床医师严格指导下用药。

The old TCM arsenic trioxide has the properties of bitterness, heat, and great toxicity. The main action site of arsenic trioxide included the lung, spleen, stomach and large intestine. The function of expectorant, and insecticides, preventing malaria. It can also be used to treat cold phlegm and asthma. In 1971, Arsenious acid injection(AAI) was used for acute promyelocytic leukemia(APL) in China, with a significantly curative effect. In 1999, Harbin Medical University Pharmaceutical Co., Ltd. was given approval to produce AASCI in China. In September 2000, AAI was approved by the FDA in the US, and in 2001 also approved in Europe. AASCI played a very important role in the treatment of solid tumors of the liver, lung, pancreas, stomach, bone, lymph and other organs, but it has rarely been used for viruses. In 1760 Zhang Zongfa described in "San Nong Ji" that the Kaer method with arsenic trioxide could cure hog cholera. Based on the Kaer therapy and application in China, we boldly propose that AASCI be used to treat NCP and other severe malignant diseases caused by multiple coronaviruses and various plague viruses. The recommended therapeutic dose is 0. 16 mg/(kg·d), the recommended medication time is 1 to 6 weeks, and other basic protective drugs should be used at the same time and guided by clinicians.